Antibodies that bind to CCR6 and their uses
The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
1. An antibody or antigen-binding fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or fragment thereof is a murine antibody, chimeric antibody or a humanized antibody.
3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region sequence comprising the amino acid sequence comprising SEQ ID NO: 37 or SEQ ID NO: 249 and wherein the antibody or fragment thereof comprises a light chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 38, SEQ ID NO: 251 or SEQ ID NO: 253.
4. The antibody or antigen-binding fragment thereof of claim 1 , wherein said antibody or fragment comprises human heavy and/or light chain constant regions and wherein the human heavy constant region is selected from the group of human immunoglobulins consisting of IGHG1, non fucosylated IGHG1 and IGHG4.
5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a full length antibody or an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fd, Fv, dAb, F(ab′)2, scFv, bispecific single chain Fv dimers, diabodies, triabodies and scFv genetically fused to the same or a different antibody.
6. A composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.
7. An immunoconjugate comprising the antibody or antigen-binding fragment thereof of claim 1 linked to a therapeutic agent.
8. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises the heavy chain CDR1 comprising: SEQ ID NO: 31; the heavy chain CDR2 comprising: SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255; and the heavy chain CDR3 comprising: SEQ ID NO: 33, and wherein the antibody or fragment thereof comprises a sequence at least 95% identical to the non-CDR region of heavy chain variable region sequence comprising SEQ ID NO: 37 or SEQ ID NO: 249.
9. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or fragment thereof comprises the light chain CDR1 comprising: SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256; the heavy chain CDR2 comprising: SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257; and the heavy chain CDR3 comprising: SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193, and wherein the antibody or fragment thereof comprises a sequence at least 95% identical to the non-CDR region of light chain variable region sequence comprising SEQ ID NO: 38, SEQ ID NO: 251, or SEQ ID NO: 253.